Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: OncoCell, Kiyatec, KDx Diagnostics

NEW YORK – OncoCell said this week that it has changed its name to Immunis.AI in order to better reflect the firm's Intelligentia platform, which examines and stratifies the risk of disease on an individual basis at the cellular level. According to the Royal Oak, Michigan firm, Intelligentia integrates RNA-Seq technology, the patient's immune system, and machine learning to develop disease-specific algorithms to detect and grade disease through simple blood tests.

Kiyatec said this week that life sciences venture investment firm Esperante has made an investment in the company. Through a spokesperson, Kiyatec declined to disclose the amount of the investment but said it is part of a Series B2 financing round and incremental to the $3 million raised in May in the round. The new investment will go toward Kyatec's pivotal 3D-Predict study to validate clinical assays that may predict pretreatment response to cancer drug treatments for ovarian cancer and glioblastoma. 

Cancer diagnostics company KDx Diagnostics has received breakthrough device designation from the US Food and Drug Administration for its URO17 Bladder Cancer Recurrence Test, which leverages a novel cancer biomarker that may improve the accuracy and sensitivity of noninvasive bladder cancer testing. In initial data published in 2018, the test demonstrated 100 percent sensitivity and 96 percent specificity in detecting recurrent bladder cancer in urine samples, the Campbell, California-based firm said. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared on 360Dx.